Hypogonadal Hypogonadism and Osteoporosis in Men

Nursing Clinics of North America

Volumn 42, Issue 1, 2007, Pages 87-99

  Romeo, June Hart ^a   Ybarra, Juan ^b  

^a MedCentral College of Nursing   (United States)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; HYPOGONADISM; MALE; NURSING; OSTEOPOROSIS; REVIEW;

HUMANS; HYPOGONADISM; MALE; OSTEOPOROSIS;

EID: 33846544924     PISSN: 00296465     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cnur.2006.11.004     Document Type: Review

References (80)

1. Kanis J.A., Johnell O., Oden A., et al. Epidemiology of osteoporosis and fracture in men. Calcif Tissue Int 75 (2004) 90-99
2. Bilezikian J.P. Commentary: osteoporosis in men. J Clin Endocrinol Metab 84 (1999) 3431-3434
3. Melton III L.J., Chrischilles E.A., Cooper C., et al. How many women have osteoporosis?. J Bone Miner Res 7 (1992) 1005-1010
4. Cooper C., and Melton III L.J. Epidemiology of osteoporosis. Trends Endocrinol Metab 3 (1992) 224-229
5. Seeman E. During aging, men lose less bone than women because they gain more periosteal bone, not because they resorb less endosteal bone. Calcif Tissue Int 69 (2001) 205-208
6. Diamond T.H., Thornley S.W., Sekel R., et al. Hip fracture in elderly men: prognostic factors and outcomes. Med J Aust 167 (1997) 412-415
7. Forsen L., Sogaard A.J., Meyer H.E., et al. Survival after hip fracture: short and long-term excess mortality according to age and gender. Osteoporos Int 10 (1999) 73-78
8. Farmer M.E., White L.R., Brody J.A., et al. Race and sex difference in hip fracture incidence. Am J Public Health 74 (1984) 1374-1380
9. Center J.R., Nguyen T.V., Schneider D., et al. Mortality after all types of osteoporotic fractures in men and women: an observational study. Lancet 353 (1999) 878-882
10. Seeman E., Bianchi G., Adami S., et al. Osteoporosis in men - consensus is premature. Calcif Tissue Int 75 (2004) 120-122
11. Nieves J.W., Formica C., Ruffing J., et al. Males have larger skeletal size and bone mass than females, despite comparable body size. J Bone Miner Res 20 (2005) 529-535
12. Seeman E. The growth and age-related origins of bone fragility in men. Calcif Tissue Int 75 (2004) 100-109
13. Peacock M., Koller D.L., Fishburn T., et al. Sex-specific and non-sex-specific quantitative trait loci contribute to normal variation in bone mineral density in men. J Clin Endocrinol Metab 90 (2005) 3060-3066
14. Jackson J.A., Kleerekoper M., Parfitt A.M., et al. Frame B: bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. J Clin Endocrinol Metab 65 (1987) 53-58
15. Khosla S., Melton III L.J., and Riggs B.L. Estrogens and bone health in men. Calcif Tissue Int 69 (2001) 189-192
16. Orwoll E.S. Treatment of osteoporosis in men. Calcif Tissue Int 75 (2004) 114-119
17. Szulc P., Munoz F., Claustrat B., et al. Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab 86 (2001) 192-199
18. Khosla S., Melton III L.J., Robb R.A., et al. Relationship of volumetric BMD and structural parameters at different skeletal sites to sex steroid levels in men. J Bone Miner Res 20 (2005) 730-740
19. Orwoll E.S. Androgens: basic biology and clinical implication. Calcif Tissue Int 69 (2001) 185-188
20. Boullion R., Bex M., Vanderschueren D., et al. Estrogens are essential for male pubertal periosteal bone expansion. J Clin Endocrinol Metab 89 (2004) 6025-6029
21. Francis R.M. Androgen replacement in aging men. Calcif Tissue Int 69 (2001) 235-238
22. Snyder P.J., Peachey H., Hannoush P., et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84 (1999) 1966-1972
23. Snyder P.J. Effects of age on testicular function and consequences of testosterone treatment. J Clin Endocrinol Metab 86 (2001) 2369-2372
24. Liu P.Y., Swerdloff R.S., and Veldhuis J.D. The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations. J Clin Endocrinol Metab 89 (2004) 4789-4796
25. Snyder P.J. Hypogonadism in elderly men - what to do until the evidence comes. N Engl J Med 350 (2004) 440-442
26. Amory J.K., Watts N.B., Easley K.A., et al. Exogenous testosterone or testosterona with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 89 (2004) 503-510
27. Barrett-Conner E., and Bhasin S. Time for (more research on) testosterone. [editorial]. J Clin Endocrinol Metab 89 (2004) 501-502
28. Behre H.M., Kliesch S., Leifke E., et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82 (1997) 2386-2390
29. Schubert M., Bullmann C., Minnemann T., et al. Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. Horm Res 60 (2003) 21-28
30. Olofsson H., Byberg L., Mohsen R., et al. Smoking and the risk of fracture in older men. J Bone Miner Res 20 (2005) 1261-1263
31. McCabe L.D., Martin B.R., McCabe G.P., et al. Dairy intakes affect bone density in the elderly. Am J Clin Nutr 80 (2004) 1066-1074
32. Nordstrom A., Karlsson C., Nyquist F., et al. Bone loss and fracture risk after reduced physical activity. J Bone Miner Res 90 (2005) 202-207
33. Ensrud K.E., Fullman R.L., Barrett-Connor E., et al. Voluntary weight reduction in older men increases hip bone loss: the Osteoporotic Fractures in Men Study. J Clin Endocrinol Metab 90 (2005) 1998-2004
34. Bischoff H.A., Stahelin H.B., Dick W., et al. Effects of vitamin D and calcium supplementation on falls, a randomized controlled trial. J Bone Miner Res 18 (2003) 343-351
35. Holick M.F. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 80 6 Suppl (2004) 1678S-1688S
36. Bischoll-Ferrari H.A., Willett W.C., Wong J.B., et al. Fracture prevention with vitamin D supplementation: a metaanalysis of randomized controlled trials. JAMA 293 (2005) 2257-2264
37. Hollis B.W., and Wagner C.L. Normal serum vitamin D levels. N Engl J Med 352 (2005) 515-516
38. Heaney R.P. Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr 80 6 Suppl (2004) 1706S-1709S
39. Dawson-Hughes B., Heaney R.P., Holick M.F., et al. Estimates of optimal vitamin D status. Osteoporos Int 16 (2005) 713-716
40. Boling E.P. Gender and osteoporosis: similarities and sex-specific differences. J Gend Specif Med 4 (2001) 36-43
41. Szulc P., Beck T.J., Marchand F., et al. Low skeletal muscle mass is associated with poor structural parameters of bone and impaired balance in elderly men-the MINOS study. J Bone Miner Res 20 (2005) 721-729
42. Janessen H.C.J.P., Samson M.M., and Verhaar H.J.J. Vitamin D deficiency, muscle function, and falls in elderly people. Am J Clin Nutr 75 (2002) 611-615
43. Bhasin S., Woodhouse L., Casaburi R., et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 90 (2005) 678-688
44. Smith M.R., McGovern F.J., Zietman A.L., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345 (2001) 948-955
45. van der Poest C.E., van Engeland M., Ader H., et al. Alendronate in the prevention of bone loss after a fracture of the lower leg. J Bone Miner Res 17 (2002) 2247-2255
46. Zehnder Y., Risi S., Knecht H., et al. Prevention of bone loss in paraplegics over 2 years with alendronate. J Bone Miner Res 19 7 (2004) 1067-1074
47. Campion J.M., and Maricic M.J. Osteoporosis in men. Am Fam Physician 67 (2003) 1521-1526
48. Kemmis K., and Stuber D. Diabetes and osteoporotic fractures: the diabetes educator's role in screening, evaluating, treating, and referring. Todays Educ 31 (2005) 187-196
49. Schwartz A.V., Sellmeyer D.E., Strotmeyer E.S., et al. Diabetes and bone loss at the hip in older black and white adults. J Bone Miner Res 20 (2005) 596-603
50. DeLaet C.E.D.H., Van Hout B.A., Burger H., et al. Hip fracture prediction in elderly men and women: validation in the Rotterdam Study. J Bone Miner Res 13 (1998) 1587-1593
51. DeLaet C.E.D.H., Van Der Klift M., Hofman A., et al. Osteoporosis in men and women: a story about bone mineral density thresholds and hip fracture risk. J Bone Miner Res 17 (2002) 2231-2236
52. Leib E.S., Lewiecki E.M., Binkley N., et al. Official positions of the International Society for Clinical Densitometry. J Clin Densitom 7 (2004) 1-5
53. Mittan D., Lee S., Miller E., et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87 (2002) 3656-3661
54. Stoch S.A., Parker R.A., Chen L., et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 86 (2001) 2787-2791
55. Daniell H.W. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 58 (2001) 101-107
56. Shahinian V., Kuo Y.F., Freeman J.L., et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 (2005) 154-164
57. Lopez A.M., Pena M.A., Hernandez R., et al. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int 16 (2005) 707-711
58. Nishiyama T., Ishizaki F., Anraku T., et al. The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab 90 (2005) 657-660
59. Agha A., Rogers B., Sherlock M., et al. Anterior pituitary dysfunction in survivors of traumatic brain injury. J Clin Endocrinol Metab 89 (2004) 4929-4936
60. Olszynski W.P., Davison K.S., Adachi J.D., et al. Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther 26 (2004) 15-28
61. Armas L.A., Hollis B.W., and Heaney R.P. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 89 (2004) 5387-5391
62. Binkley N., Drueger D., Cowgill C.S., et al. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab 89 (2004) 3152-3157
63. Sawka A.M., Thabane L., Papaioannou A., et al. A systematic review of the effect of alendronate on bone mineral density in men. J Clin Densitom 8 (2005) 7-13
64. Shimon I., Eshed V., Doolman R., et al. Alendronate for osteoporosis in men with androgen-repleted hypogonadism. Osteoporos Int 16 (2005) 1591-1596
65. Ringe J.D., Dorst A., Faber H., et al. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 24 (2004) 110-113
66. Gonnelli S., Cepollaro C., Montagnani A., et al. Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tissue Int 73 (2003) 133-139
67. Ringe J.D., Orwoll E., Daifotis A., et al. Treatment of male osteoporosis: recent advances with alendronate. Osteoporos Int 13 (2002) 195-199
68. Orwoll E., Ettinger M., Weiss S., et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 343 (2000) 604-610
69. Ringe J.D., Faber H., Farahmand P., et al. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 7 (2005) 1-5
70. Kaufman J.M., Orwoll E., Goemaere S., et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 16 (2004) 510-516
71. Orwoll E.S., Scheele W.H., Paul S., et al. The effect of teriparatide (human parathyroid hormone [1-34]) therapy on bone density in men with osteoporosis. J Bone Miner Res 18 (2003) 9-17
72. Kurland E.S., Cosman F., McMahon D.J., et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85 (2000) 3069-3076
73. Finkelstein J.S., Hayes A., Hunzelman J.L., et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349 (2003) 1216-1226
74. Lim GC, Moses AM. Resistance to the action of vitamin D in mother and daughter with asymptomatic celiac disease. Presented at the 87th Annual Meeting of the Endocrine Society. San Diego, June 4, 2005.
75. Kuehn B.M. Longer-lasting osteoporosis drugs sought. JAMA 293 (2005) 2458
76. Vermeulen A. Androgen replacement therapy in the aging male-a critical evaluation. J Clin Endocrinol Metab 86 (2001) 2380-2390
77. Rosen C.J., and Bilezikian J.P. Clinical review 123: hot topic anabolic therapy for osteoporosis. J Clin Endocrinol Metab 86 (2001) 957-964
78. Miller P.D., Bilezikian J.P., Deal C., et al. Clinical use of the teriparatide in the real world: initial insights. Endocr Pract 2 (2004) 139-148
79. Epstein S. The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. Mayo Clin Proc 80 (2005) 379-388
80. Felsenberg D., and Boonen S. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther 27 (2005) 1-11